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Bridging the knowledge gap for ocular surface squamous 
neoplasia: Africa and beyond
Ocular surface squamous neoplasia (OSSN) has emerged 
as an important manifestation of the HIV epidemic, 
especially in sub-Saharan Africa.1 This region has not 
only gained the unenviable position of having the 
highest prevalence of OSSN, but patients with HIV 
tend to present with larger tumours and have a poorer 
prognosis.2 The many factors that may contribute to 
these important features, such as co-existing human 
papillomavirus infection, immuno suppression, delayed 
access to care, and ultraviolet radiation exposure, may 
also inﬂ uence the response to therapy. 
The care providers who are tasked with making 
evidence-based treatment decisions must often 
apply the results of studies performed in dissimilar 
populations, then ﬁ lter the therapeutic options through 
the narrow sieve of what is locally feasible. A previous 
Cochrane review found a paucity of level I or II evidence 
for the treatment of OSSN in patients with HIV.3 In 
The Lancet Global Health, Gichuhi and colleagues4 provide 
helpful information to guide the care of individual 
patients with OSSN, as well as informing those who may 
inﬂ uence allocation of resources and future research. 
Their study ﬁ lls an important knowledge gap. A readily 
available topical ophthalmic medication, 5-ﬂ uorouracil, 
was found to decrease the risk of recurrence after 
excision from 36·2% to 10·6% when compared to 
placebo. At ﬁ rst glance, the speciﬁ c regimen may be 
questioned: why was cryotherapy not employed? Why 
study 5-ﬂ uorouracil when other topical agents, such as 
interferon alfa-2b and mitomycin-C, are more widely 
used among corneal specialists in developed nations? 
The answers to these questions highlight the importance 
of this study and others in delineating the best practices 
for OSSN in sub-Saharan Africa and beyond.
Recurrence of disease after surgical excision has been 
described in many regions; however, care must be 
taken when extrapolating the literature from North 
American, European, and Australian populations. While 
the risk factors for recurrence have been reasonably well 
deﬁ ned in those typically older, male, white patients, 
our understanding of OSSN in the frequently younger, 
HIV-positive patient from Africa is incomplete. At 
ﬁ rst glance, the recurrence reported in Gichuhi and 
colleagues study appears higher than in other series;5,6 
what factors contribute to this ﬁ nding remain to be 
determined. The disease itself may carry an intrinsically 
higher risk of recurrence in this population, and the 
limited availability of cryotherapy to the excision 
margins may contribute as well.7 Gichuhi and colleagues 
point out that cryotherapy is not readily available in 
the region. However, even in developed countries, 
there are few prospective, randomised trials comparing 
the evolving combinations of surgical techniques and 
adjuvant chemotherapeutic agents. The ideal approach 
to OSSN has not yet been deﬁ ned in any population, and 
the wide range of reported outcomes mandates that 
randomised controlled trials are necessary to eﬀ ectively 
answer these questions. However, the available evidence 
supports the eﬃ  cacy of cryotherapy in reducing 
recurrence after surgical excision. Opportunities 
for research and programme development include 
evaluating the cost-eﬀ ectiveness of cryotherapy 
compared to other adjuvants, such as 5-ﬂ uorouracil.
Adjuvant chemotherapy, either at the time of 
surgery or postoperatively, has generally been found 
to decrease the risk of recurrence.8 Interferon alfa-2b, 
mitomycin-C, and 5-ﬂ uorouracil have all been reported 
as eﬃ  cacious. Interferon has gained popularity, both as 
an empirical monotherapy, and as an additional therapy 
after surgical excision.9 However, several characteristics 
of this medication limit its usefulness in sub-Saharan 
Africa. Cost is a paramount barrier; although the cost of 
interferon medical therapy was found to be comparable 
to surgery in one comparison,10 that study was based on 
Medicare-allowable charges for surgery and medication 
in the USA, which may not be directly applicable to 
developing regions. It is also important to recognise that 
interferon is a protein that must be kept refrigerated 
to remain stable. This likely limits its usefulness in 
developing countries. Mitomycin would then seem to 
be a rational alternative; while it has been surpassed in 
popularity by interferon, there are a multitude of studies 
supporting the eﬃ  cacy of this agent as monotherapy, 
or in addition to surgical excision. However, 
storage at room temperature is not recommended. 
5-ﬂ uorouracil solution appears to remain stable without 
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refrigeration,11 and its general availability is encouraged 
by its place on the World Health Organization’s list of 
essential medicines.
Studies that speciﬁ cally address reducing the risk of 
recurrence in this population are welcome, and when 
viewed through the lens of pharmacoeconomics, 
provide vital guidance for health policy and the care 
of individual patients. Directions for future research 
include additional comparative trials of the eﬃ  cacy, 
safety, and cost-eﬀ ectiveness of surgery compared to 
topical chemotherapy alone, and continued eﬀ orts to 
improve access to eﬀ ective care.
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